Psilocybin-Research.comSearchable psilocybin and psilocin bibliometric database.Researcher index
Authors in the psilocybin and psilocin literature
Search researcher names, inspect publication history, find recurring topics, and create author watch alerts without collecting unverified contact lists.
Publication history
A Phase III, Multicentre, Randomised, Double-blind, Controlled Study to Investigate the Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With Treatment-resistant DepressionClinicalTrials.gov · 2026-08-10A Phase III, Multicentre, Randomised, Double-blind, Placebo-controlled Study to Investigate the Efficacy, Safety, and Tolerability of COMP360 in Participants With Treatment-resistant DepressionClinicalTrials.gov · 2026-08-10Convergent neuroimmune signaling underlying rapid antidepressant response to ketamine and psychedelics.Molecular psychiatry · 2026-07-28A Phase 3, Randomized, Double-Blind, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Psilocybin in Adults With Major Depressive Disorder (MDD)ClinicalTrials.gov · 2026-07-23Recreational drug poisonings reported to six European poison centres from 2021 to 2024.Clinical toxicology (Philadelphia, Pa.) · 2026-07-01CAPSI - Cancer Related Major Depression Treated With a Single Dose of Psilocybin: A Multicenter Randomized Placebo Controlled Double Blind Clinical TrialClinicalTrials.gov · 2026-04-13Brain-MGF: Multimodal Graph Fusion Network for EEG-FMRI Brain Connectivity Analysis Under Psilocybin2026 IEEE 23rd International Symposium on Biomedical Imaging (ISBI) · 2026-04-08Time-Dependent Effects of Rapid-Acting Antidepressants in iPSC-Derived Neurons from Treatment-Resistant Depression and Healthy Volunteers.Research square · 2026-02-12A Phase II, Multicentre, Randomised, Double-blind, Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of COMP360 in Participants With Recurrent Major Depressive DisorderClinicalTrials.gov · 2025-08-19Extraction Yields of Psilocybin and Psilocin: A Short Review of Current Methods and Their ImplicationsPharmaceuticals · 2025-03-07From Venerable Cultural Practices to Modern Psychological Solutions: Enter Entheogens into Mainstream MedicineEuropean Journal of Arts Humanities and Social Sciences · 2024-05-01Development and validation of a sensitive LC-MS-MS method to quantify psilocin in authentic oral fluid samplesJournal of Analytical Toxicology · 2023-12-12The Safety and Efficacy Of Psilocybin as an Adjunctive Therapy in Participants With Treatment Resistant DepressionClinicalTrials.gov · 2023-11-09Administration effects of four psilocybin mushroom extracts on serotonin levels and endothelial nitric oxide synthase activity levels in vivo and in vitro after one hourResearch Square · 2023-07-18Psilocybin Therapy for Major Depressive Disorder: A Systematic ReviewUndergraduate Research in Natural and Clinical Science and Technology Journal · 2023-07-17Underlying pharmacological mechanisms of psilocin-induced broadband desynchronization and disconnection of EEG in ratsFrontiers in Neuroscience · 2023-06-22Cardioprotective Potential of the Ethanol and Water Extracts of Four Psilocybin Mushrooms on Angiotensin II-Induced Hypertrophy and Oxidative Stress on H9C2 CardiomyocytesPreprints.org · 2023-06-06The Safety and Efficacy of Psilocybin in Participants With Treatment Resistant DepressionClinicalTrials.gov · 2023-04-24The Therapeutic Potential of Psilocybin in Alcohol Use Disorder Recovery: A Literature ReviewUndergraduate Research in Natural and Clinical Science and Technology (URNCST) Journal · 2023-01-05Mescaline: The forgotten psychedelic.Neuropharmacology · 2023-01-01Psychedelics, entropic brain theory, and the taxonomy of conscious states: a summary of debates and perspectives.Neuroscience of consciousness · 2023-01-01Multicentre Study To Assess Safety And Efficacy Of Psilocybin In Patients With Treatment-Resistant Depression Following Completion Of COMP 001 And COMP 003 Trials (P-TRD LTFU)ClinicalTrials.gov · 2022-09-22Molecular Structure, Reactivity and Spectroscopic Properties of Hallucinogens Psilocybin, Mescaline and their Derivatives - A Computational StudyLetters in Applied NanoBioScience · 2022-09-17Psilocybin: crystal structure solutions enable phase analysis of prior art and recently patented examplesActa Crystallographica Section A Foundations and Advances · 2022-07-29Psilocybin: crystal structure solutions enable phase analysis of prior art and recently patented examples.Acta crystallographica. Section C, Structural chemistry · 2022-01-01Psilocin, LSD, mescaline, and DOB all induce broadband desynchronization of EEG and disconnection in rats with robust translational validityTranslational Psychiatry · 2021-10-02Anti-Inflammatory Effects of Four Psilocybin-Containing Magic Mushroom Water Extracts in vitro on 15-Lipoxygenase Activity and on Lipopolysaccharide-Induced Cyclooxygenase-2 and Inflammatory Cytokines in Human U937 Macrophage Cells.DOAJ (DOAJ: Directory of Open Access Journals) · 2021-08-04Anti-Inflammatory Effects of Four Psilocybin-Containing Magic Mushroom Water Extracts in vitro on 15-Lipoxygenase Activity and on Lipopolysaccharide-Induced Cyclooxygenase-2 and Inflammatory Cytokines in Human U937 Macrophage Cells.Journal of inflammation research · 2021-01-01Effects and safety of Psilocybe cubensis and Panaeolus cyanescens magic mushroom extracts on endothelin-1-induced hypertrophy and cell injury in cardiomyocytes.Scientific reports · 2020-12-18Phytochemical, Cytotoxicity, Antioxidant and Anti-Inflammatory Effects of Magic Mushroom.Plants (Basel, Switzerland) · 2020-08-31Psilocybin-induced psychosis in humans and in rats − translational quantitative EEG studyEuropean Neuropsychopharmacology · 2016-10-01Sex differences and serotonergic mechanisms in the behavioural effects of psilocinBehavioural Pharmacology · 2016-06-01P.4.022 The impact of serotonin system modulation on behavior and quantitative EEG in an animal model of psychosis induced by psilocinEuropean Neuropsychopharmacology · 2014-03-01EPA-0137 - EEG power spectra and connectivity changes in animal serotonergic and glutamatergic models of psychosis - implications for treatmentEuropean Psychiatry · 2013-12-31